In-House vs Reference Lab Testing: Cost and Revenue
· By Dr. Tang
TL;DR: In-house testing is rarely cheaper per test than a reference lab — and that’s fine, because cost per test isn’t the point. A fluorescence analyzer returns results in 3–15 minutes versus 24–72 hours for send-out, converting diagnosis into same-day treatment. Break-even is decided by your real monthly volume, not a vendor’s spreadsheet.
Ask a clinic owner why they bought an analyzer and you’ll usually hear two words: “faster” and “cheaper.” One of those is true and one is a myth that survives because nobody runs the arithmetic. Let’s run it.
The Myth: In-House Is Cheaper per Test
Run a single cartridge through a point-of-care analyzer and the consumable alone often costs more than the reference lab’s per-test fee. The lab has scale — it buys reagents by the pallet, runs hundreds of samples a day, and amortises a lab full of equipment across all of them.
So on a strict per-test consumable basis, the reference lab usually wins. If that were the whole story, nobody would ever buy an analyzer.
It isn’t the whole story, because the comparison everyone makes is between the wrong two numbers.
The Real Comparison: Where Does the Revenue Go?
When you send a test out, the economics look like this:
- The client pays you a charge for the test.
- You pay the reference lab a fee.
- Your margin is the difference — and it’s thin.
When you run the test in-house:
- The client pays you the same charge.
- You pay for a cartridge and allocated overhead.
- You keep the entire margin.
The per-test cost went up. The per-test revenue went up more. That’s the whole game. In-house testing is a margin-capture play, not a cost-cutting play.
The Part No Spreadsheet Captures: Same-Day Treatment
Here’s the factor that flips borderline cases. When a result arrives in minutes, the clinical conversation changes:
A client brings in a vomiting dog. You suspect pancreatitis. With a quantitative cPL cartridge, you have a number in under 15 minutes — say 620 µg/L, comfortably above the ≥400 µg/L threshold consistent with pancreatitis. You start treatment that visit. The client leaves with a diagnosis, a plan, and a follow-up booked.
Send that same test out and the client goes home with “we’ll call you in a day or two.” Some of those clients never come back for the result, and the treatment starts late — or at an emergency clinic across town.
That same-day conversion is real revenue. It’s just hard to model, so most ROI calculations quietly ignore it.
The Speed Gap Is Bigger Than People Assume
A fluorescence immunoassay analyzer returns a quantitative result in roughly 3–15 minutes depending on the assay. A reference lab is 24–72 hours for routine work. For time-sensitive markers, that gap is the difference between acting and guessing:
| Marker | Why speed matters |
|---|---|
| Progesterone | Ovulation moves fast; a 48-hour delay can miss the breeding window |
| cPL | Pancreatitis is painful and progressive; treatment shouldn’t wait |
| NT-proBNP | A cardiac case may need same-day referral or stabilisation |
When the Lab Still Wins
The lab isn’t obsolete. It wins in specific situations, and being honest about them is how you avoid buying the wrong thing:
- Low monthly volume — if you run a test twice a month, the reagent expiry and QC overhead will exceed any margin you capture.
- Esoteric or batched panels — histopathology, allergy panels, and rare markers belong in a specialist lab.
- Specialist interpretation — some results need a boarded pathologist or internist’s read.
- Tests you can’t run in-clinic — no single analyzer runs everything.
The sensible model is hybrid: high-volume, time-sensitive, quantitative biomarkers in-house; everything else out.
Finding Your Break-Even
The break-even isn’t a vendor number — it’s yours to calculate:
in-house cost per test = cartridge cost + (annual QC + maintenance + training + wastage) ÷ annual volumeIf that number is below the reference lab’s fee at your real volume, in-house wins. If it’s above, send it out. The only inputs are your own practice data.
Illustrative example: a cartridge costs $12, and your annual overhead (QC, maintenance, wastage) is $1,200. At 1,200 tests a year, your fully loaded cost is $13 per test. If the lab charges you $14 for the same test, you’re $1 ahead per test before counting the same-day treatment revenue. At 300 tests a year, your cost is $16 — and the lab wins.
Same analyzer. Same cartridge. The volume changed the answer.
Application & Commercial Angle
Who should care: clinics choosing between running tests in-house and sending them out. The practical worth is speed versus volume economics — in-house wins on same-visit decisions, while reference labs win on low-volume or specialised tests.
A clinic owner should decide by patient flow and margin capture per case, keeping the analyzer for the tests that change today’s treatment plan.
FAQ
Is in-house testing always cheaper than a reference lab?
No — 1 per-test reagent cost is usually higher in-house than the lab’s fee. The advantage is earning the full client charge and enabling same-day treatment.
When does a reference lab make more sense?
For 3 scenarios — low-volume/esoteric tests, histopathology, and anything your monthly volume can’t cover; a lab also wins when you need specialist interpretation.
How much faster is in-house testing really?
A fluorescence analyzer returns a result in 3–15 minutes, versus hours to days for a reference lab — decisive for progesterone, cPL and NT-proBNP.
What is the hidden revenue of same-visit results?
A client who gets an answer in 15 minutes is far more likely to accept treatment the same day — revenue a 24–72 hour send-out structurally cannot capture.
Should I run everything in-house?
No — run a 2-side hybrid model: high-volume, time-sensitive quantitative biomarkers in-house; low-volume, esoteric or batched panels to a lab. Volume decides the line.
How do I decide where the break-even is?
Compare 1 fully loaded in-house cost per test against the reference-lab fee at your real monthly volume; if in-house is below the lab fee, in-house wins.
Key Takeaways
- In-house testing is usually not cheaper per test — 1 margin-capture strategy, not a unit-cost win.
- The hidden value is same-day diagnosis and treatment, which a 24–72 hour send-out can’t deliver.
- Speed matters most for 3 markers: progesterone, cPL, NT-proBNP.
- The reference lab still wins for 3 types of work: low-volume, esoteric, and specialist-interpretation.
- Your break-even is 1 number — your own monthly volume, not the vendor’s assumptions.
References
- Mordor Intelligence. Veterinary Point of Care Diagnostics Market (2026–2031). https://www.mordorintelligence.com/industry-reports/veterinary-point-of-care-diagnostics-market
- McCord K, et al. Spec cPL for Diagnosis of Canine Pancreatitis. Clinician’s Brief. https://www.cliniciansbrief.com/article/spec-cpl-diagnosis-canine-pancreatitis
- Raffan E, et al. The Cardiac Biomarker NT-proBNP Is Increased in Dogs. J Vet Intern Med. 2009. doi:10.1111/j.1939-1676.2009.0373.x
This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected disease should be evaluated by a veterinarian. Reference ranges are assay-dependent; always use your analyzer’s validated intervals. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.